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Purpose: Gender differences in paediatric patients with inflammatory bowel disease (IBD) are frequently reported 
as a secondary outcome and the results are divergent. To assess gender differences by analysing data collected 
within the Swiss IBD cohort study database since 2008, related to children with IBD, using the Montreal classification 
for a systematic approach. 
Methods: Data on gender, age, anthropometrics, disease location at diagnosis, disease behaviour, and therapy of 
196 patients, 105 with Crohn’s disease (CD) and 91 with ulcerative or indeterminate colitis (UC/IC) were retrieved 
and analysed. 
Results: The crude gender ratio (male : female) of patients with CD diagnosed at ＜10 years of age was 2.57, the 
adjusted ratio was 2.42, and in patients with UC/IC it was 0.68 and 0.64 respectively. The non-adjusted gender ratio 
of patients diagnosed at ≥10 years was 1.58 for CD and 0.88 for UC/IC. Boys with UC/IC diagnosed ＜10 years 
of age had a longer diagnostic delay, and in girls diagnosed with UC/IC ＞10 years a more important use of azathio-
prine was observed. No other gender difference was found after analysis of age, disease location and behaviour 
at diagnosis, duration of disease, familial occurrence of IBD, prevalence of extra-intestinal manifestations, complica-
tions, and requirement for surgery. 
Conclusion: CD in children ＜10 years affects predominantly boys with a sex ratio of 2.57; the impact of sex-hormones 
on the development of CD in pre-pubertal male patients should be investigated.
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INTRODUCTION
　Inflammatory bowel disease (IBD) includes Crohn’s 
disease (CD) and ulcerative and indeterminate (UC/IC) 
colitis. The paediatric incidence of these disorders var-
ies from 3.1 to 7.1/100,000 children per year, with great 
regional variability [1,2]. CD in children has a male pre-
ponderance [1,3,4], which is in contrast to the female 
preponderance of CD in adulthood [5]. Studies in 
paediatric patients have suggested that female children 
with CD have more severe disease, a higher prevalence 
of extra-intestinal manifestations (EIM) and hypo-al-
buminemia at diagnosis [6], and an increased risk of 
surgery [7]. Furthermore, gender differences have been 
reported for weight at diagnosis, nutritional status and 
growth failure by some groups [8-11], but not by others 
[7]. To date, no such data on paediatric patients with 
IBD are available in Switzerland. In 2006, a nationwide 
multi-centre cohort study on patients with IBD, the 
Swiss IBD cohort study (SIBDCS) was initiated [12]. 
This study has established a registry, prospectively 
monitors patients, and has included a paediatric 
sub-cohort since 2008. The aim of our study was to eval-
uate gender differences in paediatric IBD patients regis-
tered within the SIBDCS database. In accordance with 
recent reports [6], we hypothesized that we would not 
find significant differences between female and male 
patients with CD and UC regarding disease location, 
disease behaviour and therapeutic interventions, but 
that male patients would outnumber female patients. 
MATERIALS AND METHODS 
　Up to September 2012, 196 paediatric patients ≤16 
years of age, diagnosed with CD, UC, or IC according to 
standard criteria [13], were included at least four 
months after diagnosis, and registered in the SIBDCS 
database. As described by Pittet et al. [12], patients 
were recruited from the following six university cen-
tres from western through eastern Switzerland: 
Geneva, Lausanne, Bern, Basel, Zurich, and St. Gallen, 
with the University of Lausanne as coordinating cen-
tre and data base location. After approval of the study 
protocol by the central ethics committee, we retrieved 
the following two types of data from the registry: 1. 
Information obtained from the patient chart at the 
moment of enrolment, such as date of birth, gender, 
age at first symptoms, age, weight and height at IBD 
diagnosis, type of IBD (CD, UC, IC), disease location 
and behaviour at diagnosis, recorded according to the 
Montreal classification [14], the necessity for surgery, 
defined as the sum of resectional and minor perianal 
surgery, excluding non-IBD related surgeries, the 
presence of EIM (articular, ocular, cutaneous, enoral, 
hepatic) or disease complications (anaemia, growth 
failure, osteoporosis), the cumulative exposure to 
medication at inclusion, and familial occurrence of 
IBD; and 2. Measured information, such as height and 
weight obtained by the study nurse at the visit of en-
rolment, using the wall stadiometers and weight 
scales available at the various study-centres.
　Patients were grouped according to disease onset 
＜10 and ≥10 years of age as proposed by Levine et al. 
[15], and disease characteristics were analysed ac-
cording to the Montreal classification [14], in CD as in-
volving the ileum alone, colon alone, or ileo-colonic 
and upper gastrointestinal tract involvement or peria-
nal disease. Disease behaviour was stratified as in-
flammatory, stricturing, or penetrating. Disease ex-
tent in UC was analysed as involving pancolitis, left 
sided colitis and rectal disease; z-scores for height and 
weight for age were calculated according to World 
Health Organization 2007 growth charts [16], and di-
agnostic delay was defined as the interval between the 
manifestation of the first symptoms and diagnosis. 
Patients with change of diagnosis were included ac-
cording to the second diagnosis (n=7). Patients with 
IC (defined as unclassified pan-colitis) with a disease 
duration ＞3 years and no change of diagnosis (n=6), 
as well as patients diagnosed with IC at ＞10 years of 
age at diagnosis only 6-12 months before enrolment 
(n=5) were included with the UC patients.
Statistical analysis
　Continuous variables are presented as mean± 
standard deviation (SD), or-if skewed-as median 
and range, and categorical variables are presented as 
proportions and percentages. Differences between 
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Table 1. Characteristics of Patients with Ulcerative or Indeterminate Colitis
<10 years of age at diagnosis ≥10 years of age at diagnosis
Female (25) Male (17) p-value Female (26) Male (23) p-value
Age and intervals in months
　Age at diagnosis 
　Diagnostic delay 
　Disease duration
　Age at inclusion
Growth
　Median Z-score for w/a
   at diagnosis
　Median Z-score for w/a
　 at inclusion
　Median Z-score for h/a 
　 at diagnosis
　Median Z-score for h/a 
　 at inclusion
　Median Z-score for BMI/a
　 at diagnosis
　Median Z-score for BMI/a
　 at inclusion
Localization at diagnosis 
　Pancolonic
　Left colon
　Proctitis
Colectomy 
EIMs 
Complications 
FH
Exposure to treatments 
　Corticosteroids
　Azathioprine
　Anti-TNFα
　Methotrexate
87 (68.2-93.9)
2 (2.0-5.1)
35.5 (29.9-61.1)
125 (110.8-142.4)
−0.4 (−0.82-0.17)
0.08 (−0.5-0.34)
−0.21 (−0.58-0.4)
0 (−0.8-0.34)
−0.73 (−1.1-0.2)
0.3 (−0.07-0.5)
19 (76)
4 (16)
1 (4)
2 (8)
5 (20)
10 (40)
8 (32)
21 (84)
17 (68)
3 (12)
3 (12)
64 (46.2-83.7)
6 (3.2-14.2)
29 (27.6-99.4)
119 (98-158.6)
−0.59 (−0.87-0.08)
−0.2 (−0.75-−0.08)
−0.04 (−0.31-0.61)
0.1 (−1.0-0.37)
−0.7 (−1.02-−0.2)
−0.1 (−0.5-0.43)
12 (70.6)
2 (11.8)
1 (5.9)
3 (17.7)
4 (23.5)
10 (58.8)
4 (23.5)
17 (100)
14 (82.4)
6 (35.3)
3 (17.7)
0.44†
0.02†
0.41†
0.64†
0.68†
0.3†
0.59†
0.6†
0.84†
0.2†
0.78*
0.3*
0.78*
0.23*
0.55*
0.13‡
0.36‡
0.45‡
0.92‡
149.5 (144.5-159.3)
2 (1.4-10.7)
12 (10.2-20.2)
167.5 (159.6-174.6)
−0.71 (−1.15-−0.37)
0.1 (−0.47-0.4)
−0.2 (−0.63-0.33)
0.05 (−0.5-0.61)
−1.1 (−1.55-0.72)
−0.1 (−0.55-0.36)
16 (61.5)
6 (37.5)
3 (18.8)
0
7 (26.9)
14 (53.9)
3 (18.8)
20 (76.9)
19 (73.1)
1 (3.8)
4 (15.4)
156.5 (150.4-170.3)
3 (1.11-14.1)
10 (9.1-19.3)
176 (174.6-183.6)
−0.92 (−1.18-−0.05)
−0.3 (−1.04-0.24)
0.02 (−0.76-0.53)
−0.45 (−1.07-0.32)
−1.3 (−1.5-−0.6)
−0.25 (−0.88-0.27)
20 (87)
1 (4.4)
2 (8.8)
0
4 (14.4)
11 (47.8)
4 (14.4)
16 (70)
9 (39.1)
4 (14.4)
4 (14.4)
0.31†
0.61†
0.61†
0.17†
0.97†
0.12†
0.65†
0.21†
0.62†
0.63†
0.17*
0.4*
0.67*
0.56*
0.88‡
0.03‡
0.17‡
0.78‡
Values are presented as median (95% confidence interval) or number (%). 
w/a: weight for age, h/a: height for age, BMI/a: body mass index (kg/m2) for age, EIMs: extra-intestinal manifestations, FH: positive
family history, TNF: tumor necrosis factor. 
*Fisher’s exact test, †Mann Whitney U test, ‡Cox proportional hazard analysis.
groups were quantified with the two-sample t-test, 
or with the Mann-Whitney U test for continuous 
variables, and categorical variables were compared 
using the chi-squared test or Fisher’s exact test for 
small samples. To take into account disease duration 
when comparing treatment exposure, Finkelstein’s 
modified log-rank test was used to handle left- and 
interval-censored data [17]. Pearson correlation was 
used to detect any correlation between gender and 
disease variables and linear regression was used to 
assess for gender associated predictors for growth 
outcome. All statistical examinations were per-
formed with SPSS 11.0 (SPSS Inc., Chicago, IL, 
USA). R Core Team (2012; R Foundation for Statisti-
cal Computing, Vienna, Austria) has been used to 
perform Cox proportional hazard analysis.
RESULTS
　Data from 196 patients were included (105 [53.6%] 
CD, 91 [46.4%] UC/IC, 11 IC, 10 female, 1 male pa-
tient). The overall sex ratio (male : female) for CD was 
1.76, and for UC/IC 0.78. For the subgroup of children 
with disease onset ＜10 years of age the crude sex ratio 
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Table 2. Characteristics of Patients with Crohn’s Disease 
<10 years of age at diagnosis ≥10 years of age at diagnosis
Female (7) Male (18) p-value Female (31) Male (49) p-value
Age and intervals in months
　Age at diagnosis
　Diagnostic delay
　Disease duration
　Age at inclusion
Growth
　Z-score for w/a at diagnosis
　Z-score for w/a at inclusion
　Z-score for h/a at diagnosis
　Z-score for h/a at inclusion
　Z-score for BMI/a at diagnosis
　Z-score for BMI/a at inclusion
Localization at diagnosis 
　Ileal
　Colonic
　Ileo-colonic
　Upper GI
Behavior at inclusion 
　Non-stricturing,
　 non-penetrating 
　Stricturing 
　Penetrating intern 
　Penetrating perineal 
Surgical interventions 
EIMs 
Complications 
FH
Exposure to treatments 
　Corticosteroids
　Azathioprine
　Anti-TNFα
　Methotrexate
89 (−2.0-151)
11.5 (1.6-20.9)
9 (−32.9-87.5)
110.5 (−2.6-206.7)
−0.2 (−2.5-2.1)
0.15 (−2.1-2.1)
−0.84 (−2.8-1.6)
−0.25 (−2.6-2.3)
−1.33 (−2.4-0.31)
0.25 (−1.9-1.8)
0
3 (42.9)
3 (42.9)
2 (28.6)
5 (71.4)
2 (28.6)
1 (14.3)
1 (14.3)
1 (14.3)
2 (28.6)
4 (57.1)
0
5 (71.4)
4 (57.1)
4 (57.1)
3 (42.9)
91 (63.1-102.5)
5 (3.4-24.4)
24 (12.7-36.4)
112 (82.7-107.3)
−0.3 (−1.0-0.5)
−0.2 (−0.7-0.5)
0.15 (−0.7-0.3)
−0.2 (−0.9-0.2)
−0.6 (−1.26-0.14)
−0.3 (−0.5-0.7)
2 (11.1)
3 (16.7)
13 (72.2)
1 (5.6)
9 (50)
1 (5.6)
0
8 (44.4)
2 (11.1)
6 (33.3)
9 (50)
4 (22.2)
14 (77.8)
17 (94.4)
6 (33.3)
2 (11.1)
0.88†
0.8†
0.5†
0.33†
0.81†
0.62†
0.66†
0.75†
0.18†
0.72†
0.14*
0.16*
0.33*
0.11*
0.1*
0.16*
0.83*
0.82*
0.75*
0.17*
0.65‡
0.02‡
0.20‡
1.00‡
155 (150.4-166.1)
4 (1.5-14.7)
13 (11.1-23.7)
174 (168.3-183.0)
−1.26 (−1.5-−0.4)
−0.2 (−0.6-0.35)
−0.42 (−1.0-−0.1)
−0.3 (−0.8-0.1)
−1.1 (−1.7-−0.6)
−0.1 (−0.6-0.3)
3 (9.7)
5 (16.1)
22 (71)
9 (29)
20 (64.5)
4 (12.9)
2 (6.5)
10 (32.3)
6 (19.4)
9 (29)
13 (41.9)
8 (25.8)
22 (71)
27 (87.1)
13 (41.9)
7 (22.6)
153 (146.8-160.1)
4 (4.6-8.6)
14 (14.4-23.7)
177 (166.0-179.0)
−1.1 (−1.3-−0.5)
−0.5 (−1.0-−0.3)
−0.56 (−0.8-−0.1)
−0.7 (−0.9-−0.2)
−1.36 (−1.7-−1.0)
−0.5 (−0.9-−0.3)
5 (10.2)
5 (10.2)
36 (73.5)
16 (32.7)
32 (65.3)
3 (6.1)
2 (4.1)
15 (30.6)
8 (16.3)
15 (30.6)
20 (40.8)
10 (20.4)
42 (85.7)
45 (91.8)
11 (22.5)
9 (18.4)
0.48†
0.42†
0.77†
0.71†
0.55†
0.35†
0.89†
0.29†
0.99†
0.63†
0.83*
0.53*
0.94*
0.3*
0.64*
0.88*
0.73*
0.88*
0.92*
0.57*
0.13‡
0.51‡
0.14‡
0.89‡
Values are presented as median (95% confidence interval) or number (%). 
w/a: weight for age, h/a: height for age, BMI/a: body mass index (kg/m2) for age, GI: gastrointestinal tract, EIMs: extra-intestinal
manifestations, FH: positive family history, TNF: tumor necrosis factor.
*Fisher’s exact test, †Mann Whitney U test, ‡Cox proportional hazard analysis.
was 2.57, and the ratio adjusted for an age-matched 
Swiss population was 2.42 for CD, and 0.68, and 0.64, 
respectively, for UC. The sex-ratio for children ≥10 
years at diagnosis could not be adjusted. It was 1.58 for 
CD, and 0.88 for UC. 
　The birth place of children diagnosed with CD ＜10 
years of age was Switzerland in 16 of 25 (64%), United 
Kingdom in one (all 17 were Caucasian), and was un-
known in eight (32%). All four grandparents of eight 
(1 girl, 7 boys; p=0.67) patients were born in Switzer-
land and nine patients had one to four grandparents 
of Italian, Spanish, English, Danish, German, 
Austrian or Syrian origin. The birth place of children 
with UC diagnosed ＜10 years of age was Switzerland 
in 24 of 42 (57%), Chile, Spain, Italy in one case each, 
and was unknown in 15 (35.7%). All four grand-
parents of 14 of 27 children (11 boys, 7 girls) were 
born in Switzerland and 13 of 27 children had one to 
four grandparents of French, Italian, Spanish, 
German, Dutch, Belgian, Turkish, Indian, Chilean, or 
Ecuadorian origin (p=0.21). 
　There was no gender difference for maternal age at 
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Table 3. Predictive Value of Disease Duration on Change of Z-Scores between Diagnosis and Study Inclusion 
UC/IC (n)
<10 years of age at diagnosis ≥10 years of age at diagnosis
Female (25) Male (17) p-value Female (26) Male (23) p-value
Median change of z-score (95% CI) for
Weight for age
Height for age
BMI for age
0.05 (−0.4-0.8)
−0.01 (−0.4-1.2)
0.94 (0.3-1.3)
0.13 (−0.8-0.4)
−0.2 (−1.4-0.3)
0.6 (0.2-1.0)
0.4
0.76
0.24
0.52 (0.1-1.1)
0.13 (−0.2-1.1)
0.8 (0.4-1.2)
0.1 (−0.8-0.7)
−0.18 (−1.1-0.22)
1.2 (0.1-1.5)
0.06
0.06
0.8
Estimated effect size R (95% CI; p-value) of duration on
Delta z-score w/a
Delta z-score h/a
Delta z-score BMI/a
−0.0063
(−0.2-0.006; 0.29)
−0.0093
(−0.23-0.004; 0.17)
−0.0031
(−0.02-0.01; 0.64)
0.0004
(−0.01-0.01; 0.93)
−0.0089
(−0.02-0.001; 0.08)
0.0065 
(0.001-0.012; 0.02)
0.0129
(−0.02-0.04; 0.40)
0.0244 
(0.002-0.05; 0.04)
0.0004 
(−0.06-0.06; 0.99)
−0.0201 
(−0.06-0.02; 0.31)
0.0001 
(−0.04-0.04; 0.99)
−0.0228 
(−0.07-0.02; 0.30)
CD (n) Female (7) Male (18) p-value Female (31) Male (49) p-value
Median change of z-score (95% CI) for
Weight for age
Height for age
BMI for age
0.17 (−0.03-0.34)
0.27 (−1.7-2.1)
1.1 (−0.5-2.7)
0.01 (−1.7-1.2)
−0.1 (−1.2-1.0)
0.7 (−1.3-2.8)
0.7
0.52
0.4
0.2 (−1.1-2.2)
0.28 (−1.0-1.9)
−0.1 (−0.8-0.9)
0.18 (−1.2-1.0)
−0.24 (−0.5-0.14)
0.6 (−0.22-1.3)
0.16
0.33
0.63
Estimated effect size R (95% CI; p-value) of duration on
Delta z-score w/a
Delta z-score h/a
Delta z-score BMI/a
0.0051 
(−0.01-0.02; 0.37)
−0.0009 
(−0.04-0.03; 0.95)
−0.0166 
(−0.05-0.02; 0.25)
−0.0222 
(−0.05-0.003; 0.08)
−0.0051 
(−0.24-0.01; 0.56)
−0.0001 
(−0.03-0.03; 0.99)
−0.0023 
(−0.03-0.02; 0.85)
−0.0015 
(−0.02-0.02; 0.9)
−0.0019 
(−0.03-0.03; 0.88)
0.0021 
(−0.02-0.03; 0.86)
−0.0025 
(−0.02-0.01; 0.75)
0.0286 
(0.004-0.05; 0.02)
UC/IC: ulcerative and indeterminate colitis, CI: confidence interval, BMI: body mass index, w/a: weight for age, h/a: height for 
age, BMI/a: BMI for age, CD: Crohn’s disease.
birth (mean 33.3 years [SD 4.1] in boys and 29.5 [2.9] 
in girls with CD, 30.8 [4.5] in boys, 30.9 [5.3] in girls 
with UC/IC diagnosed ＜10 years of age, 29.1 [3.1] in 
boys and 30.1 [5.4] in girls with CD, and 29.3 [3.2] in 
boys and 30.6 in girls with UC/IC diagnosed ≥10 years 
of age , p=not significant [NS] in all), nor for birth or-
der (6/18 boys [six unknown] and 1/7 girls [two un-
known] with CD, 5/17 boys [eight unknown] and 7/25 
girls [eight unknown] with UC/IC diagnosed ＜10 
years of age, were firstborn, and 10/49 boys [20 un-
known] and 7/31 girls [seven unknown] with CD, and 
10/23 boys [11 unknown] and 11/26 girls [seven un-
known] with UC/IC diagnosed ≥10 years of age were 
firstborn, p=NS for all). The interval between first 
symptoms and diagnosis was significantly longer in 
boys compared to girls with disease onset ＜10 years of 
age. Azathioprine was more often required by female 
patients with UC/IC diagnosed after ≥10 and by male 
patients with CD diagnosed <10 years of age.
　No gender difference was found after comparison of 
median age at diagnosis, median disease duration be-
fore inclusion, median age at inclusion, growth param-
eters, disease localization and behaviour at diagnosis, 
requirement for surgical interventions, EIM and com-
plications before inclusion and family history of IBD 
(Tables 1 and 2) in patients with CD or UC/IC.
　Most patients changed the z-score for weight, height 
and body mass index (BMI) between diagnosis and 
study inclusion, and there was no gender difference be-
tween male and female patients (Table 3). However, a 
significant correlation between disease duration before 
inclusion and the amplitude of z-score change was 
found for the BMI of males ＞10 years of age at diag-
nosis of CD (rho=0.337, p=0.022), for the BMI of 
males ＜10 years (rho=0.61, p=0.02), and for the 
height of females ≥10 years of (rho=0.4, p=0.037) of 
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age at diagnosis of UC/IC. The duration of the disease 
under treatment had a significant impact on the 
z-score change of BMI in males with UC diagnosed 
＜10, of height in females with UC, and of BMI in 
males with CD diagnosed ≥10 years of age (Table 3). 
DISCUSSION
　The only major gender difference found in our co-
hort was the marked preponderance of boys with CD, 
and especially of boys with CD diagnosed ＜10 years. 
Several previous studies on the incidence or preva-
lence of paediatric IBD, which also included gender 
data of patients ＜17 or ≤16 years of age, such as 
those from Ohio [18], Hungary [19], and United 
Kingdom [20], Spain [21] and Scotland [22] reported 
just a small male excess, whereas others, such as stud-
ies from Toronto [23], the United Kingdom [24], 
Wisconsin [2], and Japan [25], reported a similarly 
high overall male excess as was seen in our cohort. 
However, only a few studies coming from Canada [3], 
Netherlands [26], and Sweden [27], separately report 
gender ratios for children with CD younger or older 
than 10 years of age at diagnosis, and they found ei-
ther no, or a much lower male excess than was found 
in our study.
　The current hypothesis for the adult female pre-
dominance of CD suggesting the cumulative exposure 
to endogenous and exogenous oestrogen following 
puberty as a possible trigger [28] cannot explain nei-
ther the pre-pubertal male preponderance nor the 
geo-epidemiological variability. Most of our patients 
with CD diagnosed ＜10 years of age were born in 
Switzerland, but only half of them had four grand-pa-
rents who were natives of Switzerland. Thus, the 
prevalence of X-linked polymorphisms including 
those of the DLG 5 gene, of members of the Toll-like 
receptor family [29], or of the IL-6 promoter [30] may, 
as in populations of other countries, not suffice to ex-
plain the important male excess of our CD patients. 
Local factors, including pre- or postnatal exposure to 
xeno- or phyto-oestrogens [31], and/or the admin-
istration of antibiotics causing a change of the in-
testinal microflora and thereby of the metabolism of 
sex-steroids [32,33] will have to be investigated. 
Furthermore, it is unknown whether there is a rela-
tion between adrenarche and the age at which anti-
biotics or oestrogens are administered.
　The gender ratio of our patients with UC/IC was bal-
anced in both age categories, and it was similar to the 
ratios reported by others [3,20,22], even though these 
patients shared the same environment as our CD 
patients. The lack of male excess in the UC/IC group 
may be explained by susceptibility loci that do not fa-
vour inflammation in a sex-steroid dependent way 
[34], including genes that regulate intestinal epi-
thelial barrier function, encode for cytokines and in-
flammatory mediators, or involve the HLA-DQA1 
locus.
　Besides the important male excess in CD patients 
diagnosed ＜10 years of age, we only found minor 
gender differences. In UC/IC patients, boys ＜10 years 
of age had a longer diagnostic delay, and girls ≥10 
years at diagnosis more often needed azathioprine 
therapy. These results differ from those reported by 
others [6,18] and require confirmation by the analysis 
of larger groups. 
　Older maternal age at pregnancy as a risk factor for 
CD in girls [27] or in boys [35] has previously been re-
ported [27]. No gender difference for maternal age at 
pregnancy was found in our cohort. First-born rather 
than second-born twins have been reported to be at 
higher risk of CD, but no association between birth or-
der of singletons and CD risk was found in previous 
studies [36]. No gender difference for CD was ob-
served in the first-born children of our cohort. 
　Because of the widely variable disease durations of 
our patients, though without gender difference, we 
asked whether this variability could mask gender dif-
ferences related to growth. We effectively found that 
catch-up growth, expressed as a z-score change, was 
dependant on disease duration in boys diagnosed 
with UC/IC ＜10 years, in girls with UC/IC diagnosed 
≥10 years of age, and in boys diagnosed with CD ≥10 
years of age. In these groups the z-score change was 
duration-dependent, whereas the growth dynamics 
of the remaining groups were independent of the dis-
ease duration, either because there was no growth im-
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pairment or because of persistent growth abnormal-
ities, as already described by Pfefferkorn et al. [35].
　No other gender-related differences were found in 
either disease or age group, and this finding is in ac-
cordance with the reports of other groups [6,18].
　There are several potential limitations of our study. 
Firstly, the cross-sectional nature of this study did not 
allow us to assess disease course, or growth and nu-
trition status over time. Furthermore, the Tanner stage 
was not uniformly assessed, and therefore not ad-
justed for growth and nutrition status. Additionally, 
we were not able to adjust for medication use in ana-
lyzing the BMI and height, as longitudinal use of med-
ications was not assessed. Secondly, our study was ret-
rospective and not population-based. In Switzerland, 
pubertal and post-pubertal children with IBD may be 
followed by adult gastroenterologists in private 
practice. Only pre-pubertal children are regularly fol-
lowed by the paediatric gastroenterologists of the ma-
jor regional medical centres such as those represented 
by the SIBDCS; therefore, the findings of these young-
er children are representative. Lastly, the relatively 
small number of patients ＜10 years of age at diagnosis 
required the use of non-parametric tests, which led to 
lower statistical power.
　In conclusion, except for the marked male preva-
lence in pre-pubertal CD patients, we could not observe 
any gender difference in clinical phenotypes, disease 
behaviour, or treatment, and our results are in line with 
those of previous studies reporting a lack of gender 
difference. Future studies should investigate whether 
unique or repeated antibiotic treatments during the 
pre-pubertal period result in detectable changes of se-
rum sex-steroids and/or of the quantity and function of 
invariant natural killer T cells in the intestinal mucosa, 
thereby favouring the development of CD, and whether 
there is an age at which antibiotic treatment confers a 
special risk of the development of CD.
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